Researchers Find Link between Gene, Pancreatic Cancer Malignancy
They said that the reduced gene function increases a protein that promotes metastasis and that existing drugs may be effective in suppressing the protein's functions. The finding was published in the Journal of Clinical Investigation in June.
Pancreatic cancer is the third leading cause of cancer death in Japan. The five-year survival rate is 8.5%, the worst among any cancer.
Malignant cases account for 30% to 40%, but the underlying mechanisms had not been well understood.
The team examined pancreatic cancer tissue removed during surgery and found that the decline in function of Polybromo 1, or PBRM1, a gene that regulates the expression of various proteins, is linked to greater malignancy and a higher risk of relapse.
A genetic modification to disable PBRM1 in mice with pancreatic cancer resulted in a higher malignancy rate, increased metastases and shorter survival.
The cancer cells showed an increased level of vimentin, a protein that promotes metastasis. Meanwhile, the malignancy rate and metastases decreased after mice were given a drug that suppresses vimentin.
Such correlations were also confirmed in human pancreatic cancer.
The research 'has shown that drugs to suppress vimentin effects may lead to a new treatment for highly malignant pancreatic cancer,' Kyoto University associate professor Akihisa Fukuda said. 'We hope to conduct clinical trials to realize early practical application.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
2 days ago
80 Years On: War Trauma Transforms Caring Father into Stranger
Tokyo, Aug. 8 (Jiji Press)--Eighty years after the end of World War II, the psychological scars borne by former Imperial Japanese servicemen are drawing renewed attention. Many veterans, haunted by horrific battlefield experiences, developed post-traumatic stress disorder and related conditions that continue to affect their lives and families. Such war-induced conditions, often referred to as "war trauma," can profoundly alter a person's behavior and emotional state. In one case, a father who was once devoted and loving become distant, described by a family member as merely an "empty shell" of his former self. A growing number of family members of former Japanese servicemen are coming forward to share their experiences, prompting the government to launch its first-ever survey on the realities faced by these families. The results are expected to be released within the current fiscal year to March. Akio Kuroi, 76, from Musashimurayama, Tokyo, recalls the enduring impact military service had on his father, Keijiro, a former army soldier who passed away in 1990 at the age of 77. "He was lethargic, and I couldn't even tell if he was really there. He was like an empty shell," Kuroi says. [Copyright The Jiji Press, Ltd.]
Yomiuri Shimbun
3 days ago
- Yomiuri Shimbun
Researchers Find Link between Gene, Pancreatic Cancer Malignancy
KYOTO (Jiji Press) — Researchers mainly from Kyoto University have found that impaired function of a specific gene contributes to the malignancy of pancreatic cancer, which is hard to treat with chemotherapy. They said that the reduced gene function increases a protein that promotes metastasis and that existing drugs may be effective in suppressing the protein's functions. The finding was published in the Journal of Clinical Investigation in June. Pancreatic cancer is the third leading cause of cancer death in Japan. The five-year survival rate is 8.5%, the worst among any cancer. Malignant cases account for 30% to 40%, but the underlying mechanisms had not been well understood. The team examined pancreatic cancer tissue removed during surgery and found that the decline in function of Polybromo 1, or PBRM1, a gene that regulates the expression of various proteins, is linked to greater malignancy and a higher risk of relapse. A genetic modification to disable PBRM1 in mice with pancreatic cancer resulted in a higher malignancy rate, increased metastases and shorter survival. The cancer cells showed an increased level of vimentin, a protein that promotes metastasis. Meanwhile, the malignancy rate and metastases decreased after mice were given a drug that suppresses vimentin. Such correlations were also confirmed in human pancreatic cancer. The research 'has shown that drugs to suppress vimentin effects may lead to a new treatment for highly malignant pancreatic cancer,' Kyoto University associate professor Akihisa Fukuda said. 'We hope to conduct clinical trials to realize early practical application.'
3 days ago
Japan OKs Price Cut for Alzheimer's Drug Lecanemab
News from Japan Aug 6, 2025 20:15 (JST) Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and U.S. industry peer Biogen Inc., by 15 pct in Japan starting Nov. 1. The decision is based on an assessment by the Central Social Insurance Medical Council that cited the low cost-effectiveness of the drug used to treat dementia caused by Alzheimer's disease. The price of the drug will be lowered to 97,277 yen for a 500-milligram bottle. Dosages are based on weight. For example, a patient weighing 50 kilograms would see an annual cost reduction from about 2.98 million yen to about 2.53 million yen. Lecanemab is said to be innovative because it removes abnormal proteins that accumulate in patients' brains, and is expected to slow the progression of the disease. The medication was subject to a system that adjusts drug prices based on cost-effectiveness for high-priced or large-market drugs. [Copyright The Jiji Press, Ltd.] Jiji Press
